Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

NCT07553767 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
HEPATITIS B CHRONIC
Hepatitis B Chronic Infection

Interventions

DRUG: Peginterferon alfa-2b
DRUG: TDF
DRUG: TAF
DRUG: TMF

Sponsor

Ningbo No.2 Hospital

Collaborators

[object Object]
[object Object]
[object Object]